Home Cart Sign in  
Chemical Structure| 344897-95-6 Chemical Structure| 344897-95-6

Structure of Leukadherin-1
CAS No.: 344897-95-6

Chemical Structure| 344897-95-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Leukadherin-1 is allosteric activator of CD11b/CD18 with EC50 value of 4 μM for increasing CD11b/CD18-dependent cell adhesion to fibrinogen.

Synonyms: Leukadherin-1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Leukadherin-1

CAS No. :344897-95-6
Formula : C22H15NO4S2
M.W : 421.49
SMILES Code : O=C(O)C1=CC=C(C2=CC=C(C=C(SC(N3CC4=CC=CC=C4)=S)C3=O)O2)C=C1
Synonyms :
Leukadherin-1
MDL No. :MFCD01151276
InChI Key :AEZGRQSLKVNPCI-UNOMPAQXSA-N
Pubchem ID :5342077

Safety of Leukadherin-1

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of Leukadherin-1

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Nonclassical monocytes (NCMs) 20 μM 15 minutes LA-1 pretreatment significantly reduced CXCL2 production induced by TLR agonists, LES, or HMGB1 J Clin Invest. 2022 Jul 15;132(14):e157262.
Bone marrow-derived dendritic cells (BMDCs) 20 µM 2 hours LA1 significantly inhibited LPS/IFN-γ-induced expressions of CD86 and CD40 in BMDCs and reduced the secretion of IL-6, TNF-α, IL-12, and IL-1β. Front Immunol. 2019 Feb 12;10:215.
Human monocyte-derived macrophages (HMDMs) 5 or 10 µg/ml 30 min (post-LPS priming) Confirmed LA1's inhibition of NLRP3 inflammasome in human macrophages, showing reduced IL-1β secretion. Front Immunol. 2025 Mar 6;16:1420325.
Bone marrow-derived macrophages (BMDMs) 5 µg/ml 24 hours Compared LA1 treatment to substrate stiffness effects on macrophage polarization; LA1 mimicked stiff substrates by inhibiting NLRP3 activation but uniquely reduced IL-6 secretion. Front Immunol. 2025 Mar 6;16:1420325.
Wild-type bone marrow-derived macrophages (WT BMDMs) 10 μmol/L 2 hours To investigate the effect of CD11b agonist LA-1 on macrophage adhesion, results showed that LA-1 significantly increased the number of WT BMDMs adhering to endothelial cells. J Am Heart Assoc. 2021 Apr 6;10(7):e019900.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice LLC lung cancer model Intraperitoneal injection 2 mg/kg Once daily until the end of the experiment To evaluate the effect of LA1 on tumor growth, results showed LA1 suppresses tumor growth by activating CD11b Nat Commun. 2018 Dec 19;9(1):5379
Mice APAP-induced liver injury model Intraperitoneal injection 0.4 mg/kg Administered at 6 and 12 hours after APAP administration Enhanced hepatic MMP12 mRNA and reduced necrosis in APAP-treated mice J Hepatol. 2017 Apr;66(4):787-797
Mice Allogeneic lung transplant model Intravenous injection 2 mg/kg Single dose, 2 hours before transplantation LA-1 pretreatment significantly reduced neutrophil infiltration in the lung allograft and attenuated histologic evidence of PGD J Clin Invest. 2022 Jul 15;132(14):e157262.
Mice APP transgenic mice Intraperitoneal injection 50 µM Once daily for 10 days To evaluate the effect of LA-1 on Aβ levels J Exp Med. 2017 Apr 3;214(4):1081-1092
C57BL/6 mice Endotoxic shock model Intraperitoneal injection 10, 20, 40 µg/g body weight Single injection, observed for 12 hours LA1 significantly reduced the mortality of mice, alleviated pathological injury of liver and lung, and inhibited LPS-induced pro-inflammatory response in macrophages. Additionally, LA1 reduced the levels of IL-6, TNF-α, IL-12, and IL-1β in serum. Front Immunol. 2019 Feb 12;10:215.
Mice Hypertensive cardiac remodeling model induced by Ang II or DOCA-salt Systemic administration 2.5 mg/kg Daily for 14 days To evaluate the effect of CD11b agonist LA1 on cardiac remodeling. Results showed that LA1 significantly exacerbated Ang II-induced cardiac remodeling and dysfunction. J Adv Res. 2024 Jan;55:17-31
Newborn rats Hyperoxia-induced neonatal lung injury model Intraperitoneal injection 1 mg/kg Twice daily for 14 days LA1 reduced hyperoxia-induced macrophage infiltration, improved alveolarization and vascular development, and decreased pulmonary vascular remodeling and pulmonary hypertension. Am J Respir Cell Mol Biol. 2015 Dec;53(6):793-801
ICR mice Transient middle cerebral artery occlusion model Intraperitoneal injection 1 mg/kg Once daily for 3 days Leukadherin-1 reduced brain atrophy volume and neurological deficits at 14 days after ischemia and increased synaptophysin and PSD-95 expression. J Cereb Blood Flow Metab. 2023 Mar;43(3):379-392

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.37mL

0.47mL

0.24mL

11.86mL

2.37mL

1.19mL

23.73mL

4.75mL

2.37mL

References

 

Historical Records

Categories